First Oral Treatment for Female Pattern Hair Loss Enters Phase 2/3 Trial
Female pattern hair loss (FPHL) affects more than 40% of women over 40, yet the treatment landscape has barely changed since 1991, when topical 2% minoxidil first gained FDA approval for women. No oral prescription therapy has ever been approved. Veradermics Inc., based in New Haven, Connecticut, is working to close that gap with VDPHL01.
What Makes VDPHL01 Different
VDPHL01 is an extended-release formulation of minoxidil delivered in tablet form. Its defining technology is a gel matrix system that regulates how the drug is absorbed, preventing the sharp peak concentrations that have historically linked oral minoxidil to cardiovascular side effects such as blood pressure drops, increased heart rate, and unwanted body hair growth. By smoothing the absorption curve, VDPHL01 aims to maintain therapeutic efficacy while substantially reducing these risks. Importantly, it is non-hormonal, which removes concerns for women sensitive to hormone-based interventions.
Phase 2/3 Progress
VDPHL01 is advancing under a combined Phase 2/3 design, registered as NCT07146022. This adaptive trial structure, permitted by the FDA, links both phases in sequence to accelerate the path to approval. More than 500 women have been enrolled to date. In the Phase 2 cohort of 22 women, visible hair regrowth was documented at the 2-month mark. Full Phase 2 data are anticipated before the end of 2026, after which Veradermics is expected to outline its regulatory submission timeline.
A 35-Year Treatment Gap
Oral options for male pattern hair loss, including finasteride and dutasteride, have been available for decades. Both remain contraindicated for women of childbearing potential due to teratogenic risk. The absence of an oral alternative for women is not a scientific oversight but a historically underserved gap in clinical development. VDPHL01’s non-hormonal mechanism sidesteps the reproductive safety concerns that disqualify the existing male-use agents.
What to Watch For
If Phase 2/3 results confirm efficacy and safety, VDPHL01 would become the first FDA-approved oral prescription treatment for FPHL. Pricing has not been disclosed, but existing generic oral minoxidil formulations currently sell for approximately $15~$40 per month in the US. A proprietary extended-release branded drug would likely command a higher price point. The 2026 data release will determine how quickly this moves toward a formal New Drug Application.
Frequently Asked Questions
How is VDPHL01 different from topical minoxidil? Topical minoxidil is applied directly to the scalp and can cause uneven absorption and local irritation. VDPHL01 is an extended-release oral tablet using a gel matrix that prevents sharp spikes in blood concentration, reducing side effect risk. It is also non-hormonal, making it suitable for women with hormone-related concerns.
What results have been seen so far? In the 22-woman Phase 2 cohort, visible hair growth was observed as early as 2 months after starting treatment. Full Phase 2 results are expected in 2026. Over 500 women are currently enrolled under trial ID NCT07146022.
Are there any FDA-approved oral treatments for female pattern hair loss? No FDA-approved oral prescription treatment currently exists for female pattern hair loss. Only topical 2% minoxidil holds approval for women. VDPHL01 is positioned to become the first oral option if its trials succeed.